Mazdutide (1 Vial)

Buy Mazdutide — a dual GLP-1/glucagon receptor agonist research peptide, available from PSPeptides in a 5mg vial. Every batch is manufactured in the US and verified to 99%+ purity through independent third-party testing. Researchers buy Mazdutide primarily to study body weight regulation, appetite signaling, and glucose metabolism, making it one of the most closely watched dual-agonist peptides in current incretin research, and a compound many labs now buy specifically to add to their comparative research pipeline.

What Is Mazdutide?

Mazdutide, also known by its development code IBI362, is a synthetic peptide engineered to activate both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual-agonist mechanism sets Mazdutide apart from single-target incretin peptides and places it alongside other emerging dual and triple agonists in current metabolic research.

In published trials, Mazdutide has been administered on a once-weekly subcutaneous schedule, a dosing pattern common among GLP-1-class research peptides. Researchers frequently compare Mazdutide against other GLP-1-based compounds such as semaglutide, tirzepatide, and retatrutide. For more background on how these peptides differ, see our comparison of leading GLP-1 research peptides.

Mechanism of Action: How Mazdutide Works

Mazdutide’s dual-receptor design is what distinguishes it in the research literature. By activating GLP-1R, Mazdutide engages the same pathway used by semaglutide and liraglutide, which is associated with slowed gastric emptying, increased satiety signaling, and glucose-dependent insulin secretion in preclinical models.

The second target, GCGR, is the receptor normally activated by glucagon. Concurrent activation of this receptor alongside GLP-1R is theorized to increase energy expenditure and hepatic glucose output regulation, a combination researchers believe may distinguish Mazdutide’s metabolic profile from single-target GLP-1 agonists. This dual mechanism is why many labs buy Mazdutide specifically for comparative receptor-pathway studies rather than as a straightforward GLP-1 substitute.

Mazdutide Research and Development Timeline

Mazdutide was developed by Innovent Biologics under the development code IBI362. Early-phase trials in China evaluated its safety and tolerability profile, followed by phase 2 studies in adults with type 2 diabetes and in adults with obesity or overweight. Later-phase trials expanded the dataset on glycemic and body-weight endpoints, cementing Mazdutide’s place among the current generation of dual and multi-agonist incretin peptides under active investigation.

Researchers who buy Mazdutide for comparative work often reference this development history to contextualize study design, since the compound’s clinical trial footprint is still smaller than more established GLP-1 agonists like semaglutide.

Key Research Applications of Mazdutide

• Body Weight Regulation: Mazdutide is studied for its effect on appetite signaling pathways and reduction of fat mass in research models.
• Glycemic Control: Clinical research has examined Mazdutide’s influence on insulin secretion and glucose homeostasis in models of type 2 diabetes.
• Energy Expenditure: The glucagon receptor component of Mazdutide is of interest for its role in hepatic glucose output and lipid metabolism.
• Neurometabolic Research: Preclinical work has begun exploring how dual GLP-1R/GCGR agonism may relate to diabetes-associated cognitive changes, an emerging area of peptide research.
• Lipid Metabolism: Researchers have examined how dual-receptor agonism affects lipid handling and hepatic fat accumulation in metabolic disease models.
• Comparative Incretin Research: Mazdutide is commonly used in comparative studies alongside other peptides researched for weight management.

Comparing Mazdutide to Other GLP-1 Research Peptides

Unlike single-target GLP-1 agonists, Mazdutide’s dual GLP-1R/GCGR activity differs from the GIP/GLP-1 approach used by tirzepatide and from the triple-agonist design of retatrutide. Researchers typically choose between these compounds based on which receptor pathways are relevant to their study design. Our comparison of retatrutide and tirzepatide research peptides outlines these mechanistic differences in more detail.

This side-by-side view is one reason many researchers buy Mazdutide alongside other incretin peptides — it allows direct comparative study of dual- versus single- versus triple-receptor agonism within the same lab.

Who Uses Mazdutide in Research Settings

Laboratories that buy Mazdutide range from academic metabolic research groups to contract research organizations running comparative incretin studies. Because Mazdutide’s dual-receptor profile is still less thoroughly characterized than semaglutide’s, it is frequently selected for studies specifically designed to isolate the contribution of glucagon receptor activation within a broader GLP-1 research program.

Mazdutide Product Specifications

Note: PSPeptides offers Mazdutide in a single 5mg vial size.

Quality Assurance and Testing at PSPeptides

Every time a researcher chooses to buy Mazdutide from PSPeptides, that vial has passed through a multi-step verification process. Incoming raw peptide is tested for identity and purity, and finished vials undergo an additional round of batch-specific testing before they are released for sale.

This two-stage approach is designed to catch degradation, contamination, or synthesis errors before the product reaches a research lab. Combined with US-based manufacturing, this process is central to why researchers consistently buy Mazdutide and other peptides from PSPeptides rather than unverified suppliers.